Open Access Articles- Top Results for Somatostatinoma


Classification and external resources
Specialty Oncology
ICD-O M8156/1
DiseasesDB 12277
eMedicine med/2145
NCI Somatostatinoma
Patient UK Somatostatinoma
MeSH D013005

Somatostatinoma is a malignant tumor of the delta cells of the endocrine pancreas that produces somatostatin. Increased levels of somatostatin inhibit pancreatic hormones and gastrointestinal hormones. Thus somatostatinomas are associated with mild diabetes mellitus (due to inhibition of insulin release), steatorrhoea and gallstones (due to inhibition of cholecystokinin release), and achlorhydria (due to inhibition of gastrin release). Somatostatinomas are commonly found in head of pancreas.


Main article: Somatostatin

In a normal subject actions of somatostatin include:

  • Lowers the rate of gastric emptying, and reduces smooth muscle contractions and blood flow within the intestine
  • Suppresses the release of pancreatic hormones
  • Suppresses the exocrine secretory action of pancreas.

This explains how abnormally elevated somatostatin can cause diabetes mellitus, by inhibiting insulin secretion, steatorrhoea by inhibiting cholecystokinin and secretin, gall stones by inhibiting cholecystokinin which normally induce gallbladder myocytes to contract, and hypochlorhydria caused by inhibiting gastrin, which normally stimulate acid secretion.

Somatostatinomas are associated with calcium deposits called psammoma bodies.


Treatment is by chemotherapy with streptozocin, dacarbazine, doxorubicin or by 'watchful waiting' and surgical debulking via Whipple procedure and other resections of the gastrointestinal organs affected.[1]


  1. ^ Ellison TA, Edil BH (2012). "The current management of pancreatic neuroendocrine tumors.". Adv Surg (46): 283–296. PMID 22873046.